496 related articles for article (PubMed ID: 29133060)
1. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
2. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
3. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
6. Recent innovative advances in the discovery of selective HDAC6 inhibitors.
T Tavares M; Shen S
Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379
[No Abstract] [Full Text] [Related]
7. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Osko JD; Christianson DW
Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
[TBL] [Abstract][Full Text] [Related]
8. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
Molecules; 2022 May; 27(10):. PubMed ID: 35630812
[TBL] [Abstract][Full Text] [Related]
10. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
11. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Liang YY; Zhang CM; Liu ZP
Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 in health and disease.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
15. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
17. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
[TBL] [Abstract][Full Text] [Related]
20. Exploring new histone deacetylase 6 inhibitors and their effects on reversing the α-tubulin deacetylation and cell morphology changes caused by methamphetamine.
Gupta SK; Ali KH; Lee S; Seo YH
Arch Pharm Res; 2023 Oct; 46(9-10):795-807. PubMed ID: 37777709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]